Dr James Sylvester Ebertowski Ii, MD - Medicare Urology in Ft Carson, CO

Dr James Sylvester Ebertowski Ii, MD is a medicare enrolled "Urology" physician in Ft Carson, Colorado. He graduated from medical school in 2009 and has 15 years of diverse experience with area of expertise as Urology. He is a member of the group practice Colorado Springs Urological Associates Llc, Catholic Health Initiatives Colorado and his current practice location is 1650 Cochrane Cir # B7500, Ft Carson, Colorado. You can reach out to his office (for appointments etc.) via phone at (912) 526-7115.

Dr James Sylvester Ebertowski Ii is licensed to practice in Colorado (license number 0061398) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1932336203.

Contact Information

Dr James Sylvester Ebertowski Ii, MD
1650 Cochrane Cir # B7500,
Ft Carson, CO 80913-4613
(912) 526-7115
Not Available



Physician's Profile

Full NameDr James Sylvester Ebertowski Ii
GenderMale
SpecialityUrology
Experience15 Years
Location1650 Cochrane Cir # B7500, Ft Carson, Colorado
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr James Sylvester Ebertowski Ii graduated from medical school in 2009
  NPI Data:
  • NPI Number: 1932336203
  • Provider Enumeration Date: 06/15/2009
  • Last Update Date: 03/07/2019
  Medicare PECOS Information:
  • PECOS PAC ID: 0446550701
  • Enrollment ID: I20190516000668

Medical Identifiers

Medical identifiers for Dr James Sylvester Ebertowski Ii such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1932336203NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
208800000XUrology 75616 (Georgia)Secondary
208800000XUrology 0101248205 (Virginia)Secondary
208800000XUrology 0061398 (Colorado)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Centura Health-penrose St Francis Health ServicesColorado springs, COHospital
St Mary Corwin Med Ctr, Centura HealthPueblo, COHospital
Uch-memorial Health SystemColorado springs, COHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Colorado Springs Urological Associates Llc670915539319
Catholic Health Initiatives Colorado8022927342998

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more Medical News

› Verified 7 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr James Sylvester Ebertowski Ii allows following entities to bill medicare on his behalf.
Entity NameCatholic Health Initiatives Colorado
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1356783351
PECOS PAC ID: 8022927342
Enrollment ID: O20031215000462

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more Medical News

› Verified 7 days ago

Entity NameValley View Hospital Association
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1730897109
PECOS PAC ID: 1850294778
Enrollment ID: O20040129000027

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more Medical News

› Verified 7 days ago

Entity NamePoudre Valley Medical Group Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1366763260
PECOS PAC ID: 9638208549
Enrollment ID: O20100602000122

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more Medical News

› Verified 7 days ago

Entity NameColorado Springs Urological Associates Llc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1649704826
PECOS PAC ID: 6709155393
Enrollment ID: O20170713002171

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more Medical News

› Verified 7 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr James Sylvester Ebertowski Ii is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr James Sylvester Ebertowski Ii, MD
1650 Cochrane Cir # B7500,
Ft Carson, CO 80913-4613

Ph: () -
Dr James Sylvester Ebertowski Ii, MD
1650 Cochrane Cir # B7500,
Ft Carson, CO 80913-4613

Ph: (912) 526-7115

News Archive

MILabs' new VECTor5PET/SPECT/OI/CT system installed at TUM campus in Garching

A MILabs VECTor5PET/SPECT/OI/CT system has been installed at the Chair of Pharmaceutical Radiochemistry on the TUM Campus in Garching. Under the direction of Prof. Hans-Jurgen Wester, this institute has established a broad and internationally renowned radiopharmaceutical research program, consisting of fundamental tracer development, innovative radiolabeling strategies, and the preclinical and clinical assessment of new tracers.

Final push towards elimination of Leprosy

It currently affects over 1 million people in Africa, Asia, South America, and the Pacific; and WHO estimates that between 2 and 3 million individuals are permanently disabled as a result of it. Although all the registered cases are on treatment, it is estimated that during the period 2000–2005, about 2.5 million people affected by leprosy need to be detected and treated.

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

First suicide attempts in youth more lethal than previously realized

First suicide attempts are more lethal than previously realized, reports a study of children and adolescents published in the Journal of the American Academy of Child and Adolescent Psychiatry.

Read more News

› Verified 7 days ago


Urology Doctors in Ft Carson, CO


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.